August 2012
-
Valeo Pharma has announced the launch of the Enerzair Breezhaler indacaterol / glycopyrronium / mometasone furoate and Atectura Breezhaler indacaterol / mometasone furoate DPIs in Canada. The company acquired Canadian rights to the two Novartis dry powder inhalers… Read more . . .
-
Inhalation CDMO Vectura has announced an agreement to provide preclinical development services for Incannex Healthcare’s IHL-216A CBD/isoflurane, which Incannex is developing for the treatment of traumatic brain injury. In addition to performing screening, stability, and optimization… Read more . . .
-
Oyster Point Pharma has announced the initiation of the OLYMPIA Phase 2 clinical trial of its OC-01 varenicline nasal spray for the treatment of neurotrophic keratopathy. The company’s NDA for OC-01 for the treatment of… Read more . . .
-
The FDA announced that it has approved Astepro azelastine hydrochloride nasal spray, 0.15%, for nonprescription use by adults and children aged 6 and older for the treatment of seasonal and perennial allergic rhinitis. Astepro Allergy… Read more . . .
-
ENA Respiratory said that it has raised up to AU$32 million for development of its INNA-051 pegylated TLR2/6 agonist nasal spray for the prevention of respiratory viruses, including COVID-19, and plans to initiate a Phase… Read more . . .
-
According to United Therapeutics and MannKind Corporation, the FDA has accepted United Therapeutics’ NDA for Tyvaso treprostinil DPI for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).… Read more . . .
-
Glenmark Pharmaceuticals has announced the launch of its Tiogiva tiotropium bromide DPI in the UK for the treatment of COPD. The company announced in August 2018 that it had acquired the rights to market the… Read more . . .
-
The UK Medicines and Healthcare Products Regulatory Agency (MHRA) has approved Lupin’s Luforbec beclometasone dipropionate / formoterol fumarate MDI, a generic version of Chiesi’s Fostair MDI, for the treatment of asthma and COPD, the company… Read more . . .
-
Taiba Middle East announced that it has acquired exclusive distribution and marketing rights to Insmed’s Arikayce amikacin liposome inhalation suspension in Saudi Arabia, UAE, Kuwait, Oman, Qatar, and Bahrain, the six countries that make up… Read more . . .
-
The International Society for Aerosols in Medicine (ISAM) held its 2021 Congress as a hybrid meeting, with about 40 attendees gathering in Boise, Idaho and about 150 others gathering online from around the world. Some… Read more . . .
Featured event:
5th Annual Inhaled & Nasal Biologics | DNA Forum
5th Annual Inhaled & Nasal Biologics | DNA Forum
24th-25th September 2026, Cambridge, UK
Join us for a ground-breaking and insightful forum: Two days of cutting-edge talks and networking opportunities in this complex area of drug and vaccine development.
With renowned industry leaders who will share their insights and real-world case studies, our speakers will explore innovative formulation and delivery technologies and the rationale behind overcoming development challenges. Don’t miss out on this opportunity to learn more about key topics shaping the future of inhaled therapeutics.
Get online to see speakers announced so far. Registration is live – save your seat now!
Upcoming Events
Sponsored by Intertek,, hosts of
The Inhaled & Nasal Biologics | DNA Forum
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
No events are found.